HS
JNCE

HighVista Strategies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

HighVista Strategies’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$104K – 138
2020
Q2 		$104K Buy
15,000
+4,300
+40% +$23.2K 0.09% 76
2020
Q1 		$51K Hold
10,700
– – 0.05% 43
2019
Q4 		$93K Sell
10,700
-7,600
-42% -$41.1K 0.07% 82
2019
Q3 		$61K Buy
+18,300
New +$73.3K 0.04% 107

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HighVista Strategies's JNCE Position: Q3 2020 in Review

HighVista Strategies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2020, closing a stake of 15,000 shares — an estimated $104K sold.

HighVista Strategies first reported a position in JNCE in Q3 2019 and held it in 4 quarters. The position peaked at $104K in Q2 2020. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2020.

  • HighVista Strategies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • HighVista Strategies sold 15,000 Jounce Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $104K.
  • HighVista Strategies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • HighVista Strategies's Jounce Therapeutics, Inc. Common Stock position peaked at $104K in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2020.

Based on HighVista Strategies's 13F filing for Q3 2020, filed 16 Nov 2020.